Brokerages expect that Prestige Consumer Healthcare Inc (NYSE:PBH) will announce sales of $252.05 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Prestige Consumer Healthcare’s earnings. The lowest sales estimate is $250.70 million and the highest is $254.80 million. Prestige Consumer Healthcare posted sales of $270.62 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 6.9%. The company is expected to announce its next quarterly earnings report on Thursday, February 7th.
According to Zacks, analysts expect that Prestige Consumer Healthcare will report full-year sales of $988.98 million for the current financial year, with estimates ranging from $985.00 million to $991.60 million. For the next year, analysts expect that the firm will report sales of $983.53 million, with estimates ranging from $980.20 million to $987.50 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. Prestige Consumer Healthcare had a net margin of 33.38% and a return on equity of 11.82%. The firm had revenue of $239.36 million for the quarter, compared to the consensus estimate of $236.28 million. During the same quarter in the previous year, the company earned $0.61 earnings per share. The business’s revenue was down 7.2% compared to the same quarter last year.
A number of equities research analysts have weighed in on PBH shares. Zacks Investment Research upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Wednesday, January 2nd. ValuEngine upgraded shares of Prestige Consumer Healthcare from a “sell” rating to a “hold” rating in a research note on Wednesday, November 7th. Finally, DA Davidson lifted their price target on shares of Prestige Consumer Healthcare to $38.00 and gave the stock a “neutral” rating in a research note on Monday, November 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $38.50.
PBH traded up $0.21 during trading on Friday, reaching $31.38. 221,429 shares of the company’s stock were exchanged, compared to its average volume of 380,938. Prestige Consumer Healthcare has a fifty-two week low of $27.84 and a fifty-two week high of $46.44. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.15 and a quick ratio of 1.38. The company has a market capitalization of $1.60 billion, a P/E ratio of 12.16, a P/E/G ratio of 1.53 and a beta of 1.19.
In other Prestige Consumer Healthcare news, EVP Timothy Connors sold 34,000 shares of Prestige Consumer Healthcare stock in a transaction on Monday, November 19th. The stock was sold at an average price of $38.25, for a total transaction of $1,300,500.00. Following the completion of the transaction, the executive vice president now directly owns 25,775 shares of the company’s stock, valued at $985,893.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.14% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. First Hawaiian Bank lifted its holdings in shares of Prestige Consumer Healthcare by 218.4% during the fourth quarter. First Hawaiian Bank now owns 1,210 shares of the company’s stock valued at $37,000 after acquiring an additional 830 shares during the period. Rehmann Capital Advisory Group lifted its holdings in shares of Prestige Consumer Healthcare by 4,166.4% during the third quarter. Rehmann Capital Advisory Group now owns 5,077 shares of the company’s stock valued at $134,000 after acquiring an additional 4,958 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Prestige Consumer Healthcare by 338.0% during the third quarter. Tower Research Capital LLC TRC now owns 3,754 shares of the company’s stock valued at $142,000 after acquiring an additional 2,897 shares during the period. BlueMountain Capital Management LLC bought a new position in shares of Prestige Consumer Healthcare during the second quarter valued at $208,000. Finally, Public Employees Retirement Association of Colorado lifted its holdings in shares of Prestige Consumer Healthcare by 73.8% during the third quarter. Public Employees Retirement Association of Colorado now owns 5,623 shares of the company’s stock valued at $213,000 after acquiring an additional 2,387 shares during the period.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American Over-the-Counter (OTC) Healthcare, International OTC Healthcare, and Household Cleaning. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.
Further Reading: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.